Alligator Bioscience (ATORX.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $188.6M

Market Cap: $15.4MPipeline: 7 drugs (1 Phase 3)Founded: 2001HQ: Lund, Sweden

Sector Ranking#161 in Biologics / Biosimilars #39 in Immunotherapy / Immuno-Oncology

Overview

Alligator Bioscience is a publicly traded biotech developing tumor-directed antibody therapies to combat cancer by activating the immune system directly within the tumor. Its lead candidate, the CD40 agonist mitazalimab, is preparing for Phase 3 development in first-line metastatic pancreatic cancer following highly encouraging Phase 2 results with a 24-month survival benefit. The company's strategy leverages a specialized antibody platform to create localized immunotherapies, aiming to overcome immune suppression in solid tumors while managing systemic toxicity. Recent corporate milestones include an R&D Day in August 2025 and the publication of its 2025 Annual Report.

Oncology

Technology Platform

A platform for discovering and engineering tumor-directed therapeutic antibodies, with specialized expertise in developing CD40 agonists and bispecific formats designed to locally activate the immune system within the tumor microenvironment.

Pipeline

7

7 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
mFOLFOX regimen + Mitazalimab	Biliary Tract Cancer (BTC)	Phase 2/3
CD40 agonist mitazalimab in combination with chemotherapy	Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1/2
ALG.APV-527	Solid Tumor	Phase 1/2
ATOR-1015	Solid Tumor	Phase 1
Intratumoral Mitazalimab + Intratumoral Nivolumab	Breast Cancer	Phase 1

Funding History

12

Total raised:$188.6M

PIPE$8.5MUndisclosedJun 15, 2023

Debt$10MSwedbankSep 15, 2021

Grant$2MVinnovaJun 15, 2021

PIPE$15MUndisclosedSep 15, 2020

Opportunities

Mitazalimab addresses the dire unmet need in first-line metastatic pancreatic cancer, a multi-billion dollar market with no effective immunotherapies.

Success here validates the tumor-directed CD40 approach, unlocking potential in other 'cold' tumors and positioning the company as a leader in a promising new class of immuno-oncology agents.

Risk Factors

The company faces high clinical risk as mitazalimab advances into costly Phase 3 trials, with value heavily concentrated in this single asset.

Significant dilution is likely from future equity financings needed to fund development, and commercialization will require a strategic partner, limiting profit share.

Competitive Landscape

Alligator competes in the emerging CD40 agonist space, where systemic toxicity has been a major hurdle. Its key differentiation is mitazalimab's tumor-directed design, which may offer a superior safety profile. In pancreatic cancer, it faces competition from standard chemotherapies and other investigational immunotherapies, but its reported 24-month survival data, if confirmed, could set a new benchmark.